DoD Kideny Cancer, Technology Development Award

The summary for the DoD Kideny Cancer, Technology Development Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Kideny Cancer, Technology Development Award: The KCRP Technology Development Award is a product-driven award mechanism intended to advance the development of technologies to aid kidney cancer clinical and patient outcomes, including prevention, detection, diagnosis, treatment, or quality of life. Applicants with limited kidney cancer experience are strongly encouraged to collaborate with those having substantial expertise in kidney cancer research and/or kidney cancer model systems. Applications must describe how the technology will enhance the existing knowledge of kidney cancer. The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device. The Principal Investigator (PI) must provide a transition plan (including potential funding and resources) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the KCRP award. Applications must include preliminary data relevant to the proposed phase of development (data does not have to be in kidney cancer). Informative clinical data from a related human disease may be used to support the rationale for the proposed study. These data may be unpublished and/or from the published literature. Investigators seeking to identify a product should consider submitting to the FY18 KCRP Concept Award (W81XWH-18-KCRP-CA) or the FY18 KCRP Idea Development Award (W81XWH-18-KCRP-IDA), as appropriate. Examples of the types of research that may be supported include, but are not limited to: Use of artificial intelligence to identify novel targets for kidney cancer therapy and/or biomarkers of response/resistance to therapeutics. Platform development or adaptation to provide ultrasensitive, multiplexed detection of genomic, proteomic, and metabolic biomarkers to determine renal cell carcinoma (RCC) molecular phenotype and/or disease status from a single biological sample (e.g., tissue, blood, urine). Technology application to enable dissemination of accurate and up-to-date kidney cancer information to patients and caregivers. Development of a virtual annotated tumor bank that may be used by the research community as a resource to study molecular characteristics, disease status, population demographics, etc. Licensing and Commercialization Partners: Applicants are encouraged to identify and foster relationships with potential licensing and commercialization partners early in the development process. Biotechnology or pharmaceutical companies intending to apply for the Therapeutic Development Award are encouraged to leverage their own resources to complement the funding provided by this award. Participating organizations should ensure the success of the collaboration by resolving potential intellectual and material property issues and by removing organizational barriers that might interfere with achieving high levels of cooperation. Letters confirming/supporting the collaboration are required. The anticipated direct costs budgeted for the entire period of performance for an FY18 KCRP Technology Development Award will not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.